Collegium Pharmaceutical, Inc. (COLL)
USD 27.65
(2.18%)
USD 27.65
(2.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 159.2 Million USD | -9.63% |
| 2022 | 176.16 Million USD | 37.19% |
| 2021 | 128.41 Million USD | 3.89% |
| 2020 | 123.6 Million USD | -2.51% |
| 2019 | 126.78 Million USD | -6.37% |
| 2018 | 135.42 Million USD | 33.65% |
| 2017 | 101.32 Million USD | 6.01% |
| 2016 | 95.58 Million USD | 255.22% |
| 2015 | 26.9 Million USD | 52.32% |
| 2014 | 17.66 Million USD | 10.12% |
| 2013 | 16.04 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 43.33 Million USD | 3.22% |
| 2024 Q1 | 41.98 Million USD | 27.44% |
| 2023 Q1 | 52.77 Million USD | 38.76% |
| 2023 Q3 | 35.29 Million USD | -7.58% |
| 2023 Q2 | 38.19 Million USD | -27.63% |
| 2023 FY | 159.2 Million USD | -9.63% |
| 2023 Q4 | 32.94 Million USD | -6.67% |
| 2022 Q3 | 38.37 Million USD | -6.99% |
| 2022 FY | 176.16 Million USD | 37.19% |
| 2022 Q1 | 58.51 Million USD | 107.4% |
| 2022 Q4 | 38.03 Million USD | -0.89% |
| 2022 Q2 | 41.25 Million USD | -29.49% |
| 2021 FY | 128.41 Million USD | 3.89% |
| 2021 Q4 | 28.21 Million USD | -11.74% |
| 2021 Q1 | 34.4 Million USD | 17.44% |
| 2021 Q2 | 33.83 Million USD | -1.67% |
| 2021 Q3 | 31.96 Million USD | -5.52% |
| 2020 Q4 | 29.29 Million USD | 2.55% |
| 2020 Q3 | 28.56 Million USD | -10.21% |
| 2020 Q2 | 31.81 Million USD | -6.22% |
| 2020 FY | 123.6 Million USD | -2.51% |
| 2020 Q1 | 33.92 Million USD | 23.42% |
| 2019 Q4 | 27.48 Million USD | -15.59% |
| 2019 Q3 | 32.56 Million USD | 3.72% |
| 2019 Q2 | 31.39 Million USD | -11.18% |
| 2019 FY | 126.78 Million USD | -6.37% |
| 2019 Q1 | 35.34 Million USD | 8.09% |
| 2018 Q2 | 33.51 Million USD | -0.99% |
| 2018 Q1 | 33.85 Million USD | 24.07% |
| 2018 Q4 | 32.7 Million USD | -7.51% |
| 2018 FY | 135.42 Million USD | 33.65% |
| 2018 Q3 | 35.35 Million USD | 5.49% |
| 2017 Q4 | 27.28 Million USD | 9.89% |
| 2017 Q3 | 24.82 Million USD | 2.42% |
| 2017 Q1 | 24.97 Million USD | -12.97% |
| 2017 FY | 101.32 Million USD | 6.01% |
| 2017 Q2 | 24.24 Million USD | -2.95% |
| 2016 Q4 | 28.69 Million USD | 7.0% |
| 2016 FY | 95.58 Million USD | 255.22% |
| 2016 Q3 | 26.82 Million USD | 9.59% |
| 2016 Q2 | 24.47 Million USD | 57.02% |
| 2016 Q1 | 15.58 Million USD | 65.19% |
| 2015 FY | 26.9 Million USD | 52.32% |
| 2015 Q3 | 9.26 Million USD | 102.51% |
| 2015 Q2 | 4.57 Million USD | 26.03% |
| 2015 Q1 | 3.63 Million USD | 9.11% |
| 2015 Q4 | 9.43 Million USD | 1.85% |
| 2014 Q4 | 3.32 Million USD | -48.85% |
| 2014 FY | 17.66 Million USD | 10.12% |
| 2014 Q3 | 6.5 Million USD | 59.12% |
| 2014 Q1 | 3.74 Million USD | 0.0% |
| 2014 Q2 | 4.08 Million USD | 9.19% |
| 2013 FY | 16.04 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 271.89 Million USD | 41.445% |
| Theratechnologies Inc. | 72.75 Million USD | -118.825% |
| Safety Shot Inc | 12.1 Million USD | -1214.715% |
| Cosmos Health Inc. | 26.18 Million USD | -508.11% |
| Cronos Group Inc. | 96.7 Million USD | -64.626% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 31.413% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -306.63% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 49.318% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1050.188% |
| ProPhase Labs, Inc. | 37.85 Million USD | -320.607% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -1585.454% |
| Dynavax Technologies Corporation | 219.14 Million USD | 27.35% |
| Radius Health, Inc. | 265.92 Million USD | 40.131% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -5087.3% |
| Alvotech | 285.43 Million USD | 44.223% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1113.062% |
| Alpha Teknova, Inc. | 45.85 Million USD | -247.168% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 73.016% |
| SCYNEXIS, Inc. | 51.84 Million USD | -207.067% |
| Harrow Health, Inc. | 89.97 Million USD | -76.951% |
| Biofrontera Inc. | 39.95 Million USD | -298.428% |
| DURECT Corporation | 43.71 Million USD | -264.195% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 69.905% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 18.764% |
| OptiNose, Inc. | 85.1 Million USD | -87.079% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 1765.181% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -254.947% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -269.902% |
| SIGA Technologies, Inc. | 22.04 Million USD | -622.26% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -224.663% |
| Shineco, Inc. | 17.94 Million USD | -787.05% |
| Phibro Animal Health Corporation | 260.29 Million USD | 38.836% |
| Procaps Group S.A. | 187.24 Million USD | 14.973% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -1520.438% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -3889.038% |
| Viatris Inc. | 5.96 Billion USD | 97.331% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1113.062% |
| Rockwell Medical, Inc. | 15.37 Million USD | -935.567% |
| Incannex Healthcare Limited | 30.05 Million USD | -429.757% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -166.056% |
| Tilray Brands, Inc. | 251.35 Million USD | 36.661% |
| PetIQ, Inc. | 192.72 Million USD | 17.391% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -20779.957% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 90.028% |
| Journey Medical Corporation | 54.59 Million USD | -191.622% |
| Alimera Sciences, Inc. | 62.64 Million USD | -154.159% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -793.998% |
| Assertio Holdings, Inc. | 368.58 Million USD | 56.806% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -2605.056% |
| Embecta Corp. | 528.4 Million USD | 69.87% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -656.617% |
| Procaps Group, S.A. | 199.47 Million USD | 20.187% |
| PainReform Ltd. | 9.58 Million USD | -1561.185% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 3.49% |
| Hempacco Co., Inc. | 7.59 Million USD | -1995.821% |
| Talphera, Inc. | 11.99 Million USD | -1227.397% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 51.22% |
| Alvotech | 285.43 Million USD | 44.223% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 53.84% |
| Kamada Ltd. | 45.42 Million USD | -250.478% |
| Indivior PLC | 911 Million USD | 82.524% |
| Currenc Group, Inc. | 24 Million USD | -563.309% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1182.938% |
| Flora Growth Corp. | 10.57 Million USD | -1404.944% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -656.617% |
| Evolus, Inc. | 189.75 Million USD | 16.1% |
| HUTCHMED (China) Limited | 436.23 Million USD | 63.504% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -3.292% |
| Akanda Corp. | 3.48 Million USD | -4470.335% |